

Table 2. Characteristics of Nonsteroidal Use among Case-Patients*

Characteristic	No NSAID Use (n = 1354)	Celecoxib Use (n = 18)	Rofecoxib Use (n = 27)	Nonselective NSAID Use (n = 319)
Sociodemographic				
Age, y	58.67 ± 9.10	60.50 ± 9.28	60.52 ± 8.82	57.46 ± 9.13†
Insurance, n (%)				
Medicare	246 (18.8)	5 (31.3)	9 (36.0)	57 (18.1)
Medicaid/Veterans	44 (3.4)	0 (0.0)	0 (0.0)	16 (5.1)
Private	963 (73.6)	11 (68.8)	16 (64.0)	232 (73.7)
None	55 (4.2)	0 (0.0)	0 (0.0)	10 (3.2)
Race, n (%)				
White	974 (72.8)	11 (61.1)	17 (65.4)	233 (73.5)
Black	320 (23.9)	6 (33.3)	9 (34.6)	76 (24.0)
Other	44 (3.3)	1 (5.6)	0 (0.0)	8 (2.5)
Duration of education, y	13.24 ± 2.71	13.53 ± 2.27	13.12 ± 2.18	13.12 ± 2.65
Clinical				
Physical activity score‡	7.01 ± 1.28	6.90 ± 1.06	7.14 ± 0.97	7.14 ± 1.33
BMI, kg/m ²	29.16 ± 6.01	28.38 ± 5.18	29.42 ± 6.77	30.17 ± 6.38†
Cigarette smoking, n (%)				
Past	472 (35.1)	4 (22.2)	8 (29.6)	112 (35.2)
Current	448 (33.3)	7 (38.9)	10 (37.0)	115 (36.2)
Diabetes mellitus, n (%)	324 (23.9)	3 (16.7)	2 (7.4)	51 (16.0)†
Family history of coronary disease, n (%)	563 (41.6)	7 (38.9)	4 (14.8)§	150 (47.2)
Women, n (%)	470 (34.8)	10 (55.6)	17 (63.0)§	131 (41.1)†
History of congestive heart failure, n (%)	58 (4.3)	2 (11.1)	1 (3.7)	11 (3.4)
Hypercholesterolemia, n (%)	626 (46.2)	11 (61.1)	18 (66.7)§	172 (53.9)†
Hypertension, n (%)	744 (54.9)	13 (72.2)	12 (44.4)	179 (56.1)
Previous angina or coronary disease, n (%)	246 (18.2)	3 (16.7)	6 (22.2)	46 (14.4)
Self-reported osteoarthritis, n (%)	80 (5.9)	2 (11.1)	7 (25.9)§	49 (15.4)†
Self-reported rheumatoid arthritis, n (%)	55 (4.1)	5 (27.8)	3 (11.1)	25 (7.9)†
Self-reported renal disease, n (%)	29 (2.1)	1 (5.6)	0 (0.0)	1 (0.3)†
History of gastrointestinal ulcer disease, n (%)	109 (8.1)	4 (22.1)	1 (3.7)	21 (6.6)
Medication use, n (%)				
ACE inhibitors	234 (17.3)	5 (27.8)	2 (7.4)	46 (14.4)
Aspirin	447 (33.0)	8 (44.4)	10 (37.0)	113 (35.4)
β-Blockers	212 (15.7)	3 (16.7)	5 (18.5)	52 (16.3)
Calcium-channel blockers	241 (17.8)	3 (16.7)	5 (18.5)	57 (17.9)
Diuretics	188 (13.9)	7 (38.9)	5 (18.5)	55 (17.2)
HMG-CoA reductase inhibitors	298 (22.0)	7 (38.9)	10 (37.0)	66 (20.7)
Physician visits per y, n	6.77 ± 19.28	16.47 ± 42.30	11.89 ± 25.08	6.42 ± 10.71

* Values expressed with a plus/minus sign are means ± SD. ACE = angiotensin-converting enzyme; BMI = body mass index; HMG-CoA = 3-hydroxy-3-methylglutaryl coenzyme A; NSAID = nonsteroidal anti-inflammatory drug.

† *P* < 0.05 comparing nonselective NSAIDs with no NSAIDs.

‡ Validated physical activity score (25). Higher score represents greater physical activity.

§ *P* < 0.05 comparing rofecoxib with no NSAIDs.

|| *P* < 0.05 comparing celecoxib with no NSAIDs.